Management of adjuvant S-1 therapy after curative resection of gastric cancer: Dose reduction and treatment schedule modification

Gastric Cancer

Volumn 14, Issue 1, 2011, Pages 28-34

  Iwasa, Satoru ^a   Yamada, Yasuhide ^a   Fukagawa, Takeo ^a   Eguchi Nakajima, Takako ^a   Kato, Ken ^a   Hamaguchi, Tetsuya ^a   Morita, Shinji ^a   Saka, Makoto ^a   Katai, Hitoshi ^a   Shimada, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Adjuvant chemotherapy; Gastric cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATININE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EPIPHORA; FATIGUE; FEMALE; GASTRECTOMY; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PANCREAS FISTULA; PIGMENT DISORDER; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; STOMACH CANCER; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR RECURRENCE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR;

EID: 79953030115     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-011-0003-y     Document Type: Article

References (19)

1. JR Kelley JM Duggan 2003 Gastric cancer epidemiology and risk factors J Clin Epidemiol 56 1 9 12589864 10.1016/S0895-4356(02)00534-6 (Pubitemid 36183309)
2. JS Macdonald SR Smalley J Benedetti SA Hundahl NC Estes GN Stemmermann, et al. 2001 Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725 730 11547741 10.1056/NEJMoa010187 1:STN:280:DC%2BD3Mvps1Cqug%3D%3D
3. D Cunningham WH Allum SP Stenning JN Thompson CJ Van de Velde M Nicolson, et al. 2006 Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11 20 16822992 10.1056/NEJMoa055531 1:CAS:528:DC%2BD28Xms1Chsrw%3D
4. M Sasako T Sano S Yamamoto Y Kurokawa A Nashimoto A Kurita, et al. 2008 D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer N Engl J Med 359 453 462 18669424 10.1056/NEJMoa0707035 1:CAS:528: DC%2BD1cXpt1Shu7Y%3D
5. T Kinoshita A Nashimoto Y Yamamura T Okamura M Sasako J Sakamoto, et al. 2004 Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer Gastric Cancer 7 104 109 15224197 10.1007/s10120-004-0278-3 1:CAS:528:DC%2BD2cXlt1Gluro%3D (Pubitemid 38899661)
6. T Nakajima T Kinoshita A Nashimoto M Sairenji T Yamaguchi J Sakamoto, et al. 2007 Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer Br J Surg 94 1468 1476 17948223 10.1002/bjs.5996 1:CAS:528:DC%2BD1cXhtFKhurk%3D (Pubitemid 350275624)
7. T Kato Y Shimamoto J Uchida H Ohshimo M Abe T Shirasaka, et al. 2001 Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil Anticancer Res 21 1705 1712 11497250 1:CAS:528: DC%2BD3MXmt1eru7g%3D (Pubitemid 32728903)
8. Y Yamada T Hamaguchi M Goto K Muro Y Matsumura Y Shimada, et al. 2003 Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil Br J Cancer 89 816 820 12942110 10.1038/sj.bjc.6601224 1:CAS:528: DC%2BD3sXms1Gku78%3D (Pubitemid 37175800)
9. S Sakuramoto M Sasako T Yamaguchi T Kinoshita M Fujii A Nashimoto, et al. 2007 Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810 1820 17978289 10.1056/NEJMoa072252 1:CAS:528:DC%2BD2sXht1Kit7bI (Pubitemid 350044801)
10. Japanese Gastric Cancer Association 1998 Japanese classification of gastric carcinoma-2nd English edition Gastric Cancer 1 10 24 11957040 10.1007/PL00011681
11. T Yamanaka S Matsumoto S Teramukai R Ishiwata Y Nagai M Fukushima 2008 Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3758 patients Cancer Chemother Pharmacol 61 335 343 17922276 10.1007/s00280-007-0595-4 1:CAS:528: DC%2BD2sXhtlWrs7zM (Pubitemid 350160333)
12. CJ van Groeningen GJ Peters JH Schornagel H Gall P Noordhuis MJ de Vries, et al. 2000 Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors J Clin Oncol 18 2772 2779 10894878 (Pubitemid 30463561)
13. PM Hoff ED Saad JA Ajani Y Lassere C Wenske D Medgyesy, et al. 2003 Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors Clin Cancer Res 9 134 142 12538461 1:CAS:528:DC%2BD3sXnt1Omtw%3D%3D (Pubitemid 36109725)
14. QS Chu LA Hammond G Schwartz L Ochoa SY Rha L Denis, et al. 2004 Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies Clin Cancer Res 10 4913 4921 15297391 10.1158/1078-0432.CCR-04-0469 1:CAS:528:DC%2BD2cXmtlSisbk%3D (Pubitemid 39099764)
15. SJ Cohen CG Leichman G Yeslow M Beard A Proefrock B Roedig, et al. 2002 Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer Clin Cancer Res 8 2116 2122 12114411 1:CAS:528:DC%2BD38XmtVWitbs%3D (Pubitemid 34753581)
16. M Kochi M Fujii N Kanamori T Kaiga K Aizaki T Takahashi, et al. 2007 Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients Cancer Chemother Pharmacol 60 693 701 17690883 10.1007/s00280-007-0415-x 1:CAS:528:DC%2BD2sXovFSrtrs%3D (Pubitemid 47247281)
17. WY Kim B Nakata K Hirakawa 2007 Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy Cancer Sci 98 1604 1608 17683513 10.1111/j.1349-7006.2007.00573.x 1:CAS:528:DC%2BD2sXhtF2qtb%2FF (Pubitemid 47308458)
18. Y Tsuruoka T Kamano M Kitajima K Kawai S Watabe T Ochiai, et al. 2006 Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1 Anticancer Drugs 17 393 399 16549996 10.1097/01.cad.0000203382.07114.0f 1:CAS:528:DC%2BD28Xis1Sis7k%3D (Pubitemid 44309981)
19. S Sakuramoto S Kikuchi M Watanabe 2009 Efficacy of S-1 (oral fluoropyrimidine) for gastric cancer The Medical Frontline (Saishin Igaku) 64 1075 1080 (in Japanese)